Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).
Sumanta K. Pal(City of Hope), Sun Young Rha(Yonsei University), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Daniel Castellano(Universidad Complutense de Madrid), Karen O’Hara(Eisai (United States)), Kaisa Sunela(Tampere University Hospital), Lixian Peng(Eisai (United States)), Jae‐Lyun Lee(Ulsan College), Javier Puente(Hospital Clínico San Carlos), Daniil Stroyakovskiy(Shikoku Cancer Center), P. Koralewski(Unknown), Alan D. Smith(Eisai (Japan)), Terri A. Binder(Eisai (United States)), Francis Parnis(Centre for Cancer Biology), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Daniel Yick Chin Heng(University of Calgary), Hilary Glen(Beatson West of Scotland Cancer Centre)
Cited by 11
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k